Complement inhibitor eculizumab in thrombotic microangiopathy: Single‐center case series

Monika Vitkauskaitė(Vilnius University), Artūras Vinikovas(Vilnius University), Marius Miglinas(Vilnius University), Laurynas Rimševičius(Vilnius University), Agnė Čerkauskaitė(Vilnius University), Ernesta Mačionienė(Vilnius University), Eglė Ašakienė(Vilnius University)
Clinical Case Reports
March 1, 2022
Cited by 1Open Access
Full Text

Abstract

Our case series showed that eculizumab is efficacious and safe in treating thrombotic microangiopathy, as well as it has positive effects on quality of life. Further extensive studies are required to develop unified treatment guidelines.


Related Papers

No related papers found

Powered by citation graph analysis